Tscan Therapeutics Inc (NASDAQ: TCRX) kicked off on Tuesday, up 17.24% from the previous trading day, before settling in for the closing price of $1.45. Over the past 52 weeks, TCRX has traded in a range of $1.02-$7.89.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -14.41% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded -10.90%. With a float of $43.83 million, this company’s outstanding shares have now reached $52.31 million.
In an organization with 194 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 58.67%, operating margin of -3159.87%, and the pretax margin is -2974.08%.
Tscan Therapeutics Inc (TCRX) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Tscan Therapeutics Inc is 22.56%, while institutional ownership is 71.35%. The most recent insider transaction that took place on May 19 ’25, was worth 1,666,553. In this transaction 10% Owner of this company bought 1,388,794 shares at a rate of $1.20, taking the stock ownership to the 6,746,141 shares. Before that another transaction happened on May 20 ’25, when Company’s 10% Owner bought 1,200,000 for $1.20, making the entire transaction worth $1,440,000. This insider now owns 7,946,141 shares in total.
Tscan Therapeutics Inc (TCRX) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -10.90% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 9.18% during the next five years compared to -14.41% drop over the previous five years of trading.
Tscan Therapeutics Inc (NASDAQ: TCRX) Trading Performance Indicators
Take a look at Tscan Therapeutics Inc’s (TCRX) current performance indicators. Last quarter, stock had a quick ratio of 8.55. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 21.77.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.09, a number that is poised to hit -0.33 in the next quarter and is forecasted to reach -1.18 in one year’s time.
Technical Analysis of Tscan Therapeutics Inc (TCRX)
Let’s dig in a bit further. During the last 5-days, its volume was 0.35 million. That was inferior than the volume of 0.51 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 46.52%.
During the past 100 days, Tscan Therapeutics Inc’s (TCRX) raw stochastic average was set at 51.91%, which indicates a significant decrease from 91.18% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1387 in the past 14 days, which was lower than the 0.1525 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.4907, while its 200-day Moving Average is $2.8200. However, in the short run, Tscan Therapeutics Inc’s stock first resistance to watch stands at $1.7996. Second resistance stands at $1.8992. The third major resistance level sits at $2.0690. If the price goes on to break the first support level at $1.5302, it is likely to go to the next support level at $1.3604. Assuming the price breaks the second support level, the third support level stands at $1.2608.
Tscan Therapeutics Inc (NASDAQ: TCRX) Key Stats
The company with the Market Capitalisation of 96.21 million has total of 56,591K Shares Outstanding. Its annual sales at the moment are 2,820 K in contrast with the sum of -127,500 K annual income. Company’s last quarter sales were recorded 2,170 K and last quarter income was -34,130 K.
